Tibetan medicine maker best known for herbal plaster patches used to treat joint and muscle pain.
Tibetan medicine maker best known for herbal plaster patches used to treat joint and muscle pain.
In one line: A Chinese Tibetan-medicine Salonpas maker.
Moat: narrow (brand, IP / patents). Distinctive Tibetan-medicine brand and formula recipes not easily replicated by mainstream TCM makers.
Headquarters: Lhasa, Tibet, China · Employees: 3,203
Size Tibet Cheezheng Tibetan Medicine (002287.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.58B, the 1456th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.51 on 18 Nov 2026.
Performance Over six months the shares fell 17.1%, against -1.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median +11.3%); the operating margin is 27.6% (peer median 15.0%).
Valuation It trades at 4.0× enterprise value to sales against a peer median of 3.0× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.0 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.23B | CN¥2.39B | CN¥2.31B | CN¥2.02B | CN¥2.02B |
| Revenue growth | — | +3% | +14% | 0% | — |
| Gross profit | CN¥1.90B | CN¥1.92B | CN¥1.84B | CN¥1.64B | CN¥1.64B |
| EBITDA | n/a | CN¥744M | CN¥675M | CN¥562M | CN¥611M |
| Net income | CN¥632M | CN¥648M | CN¥582M | CN¥581M | CN¥473M |
| Free cash flow | CN¥353M | CN¥651M | CN¥273M | CN¥737M | CN¥43.8M |
| Capital expenditure | CN¥147M | CN¥153M | CN¥255M | CN¥235M | CN¥272M |
| Total debt | CN¥935M | CN¥1.02B | CN¥1.76B | CN¥1.55B | CN¥1.74B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine 002287.SZ | $1.58B | -17% | -7% | 28% | 4.0× | -1.9% |
| Henan Lingrui Pharmaceutial 600285.SS | $2.04B | +9% | +5% | 22% | 3.3× | -4.7% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002287.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.8% | -1.2% | 8th lowest of 21 |
| 6-month return | -17.1% | -1.6% | 6th lowest of 21 |
| Distance from 52-week high | -29.8% | -23.4% | 9th lowest of 21 |
| Revenue growth (TTM) | -6.5% | +11.3% | 3rd lowest of 21 |
| Operating margin | 27.6% | 15.0% | 4th highest of 21 |
| EV / Sales | 4.0× | 3.0× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -1.9% | 2.8% | 6th least demanding of 19 |
| Growth delivered (Del g) | +10.4% | +10.5% | 9th lowest of 19 |
| Hurdle (Req g minus delivered) | -12.2 pp | -10.5 pp | 9th least demanding of 19 |
| ROIC minus cost of capital | +10.0 pp | +2.7 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | 4.0× | -1.9% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 0.9× | -7.8% | +3.9% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | 3.1× | 2.1% | +10.4% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 19.3× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 2.7× | 13.5% | +15.3% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | 0.6× | -1.3% | -2.1% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 3.0× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 7.4× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 4.2× | 10.6% | -3.9% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 3.3× | 23.6% | +10.6% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 2.4× | 18.8% | +26.7% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 1.3× | -1.7% | +4.4% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 4.8× | 13.1% | +62.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 4.0× | -1.9% | +11.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 1.5× | -9.1% | +5.3% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 2.9× | -8.7% | +5.5% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 1.0× | -2.1% | +7.1% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 4.6× | 24.6% | +38.5% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 2.0× | 4.8% | +0.6% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 2.9× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 5.6× | 4.7% | +18.5% |